Phenothiazine-Based LSD1 Inhibitor Promotes T-Cell Killing Response of Gastric Cancer Cells.

Histone lysine specific demethylase 1 (LSD1) has been recognized as an important epigenetic target for cancer treatment. Although several LSD1 inhibitors have entered clinical trials, the discovery of novel potent LSD1 inhibitors remains a challenge. In this study, the antipsychotic drug chlorpromazine was characterized as an LSD1 inhibitor (IC50 = 5.135 μM), and a series of chlorpromazine derivatives were synthesized. Among them, compound 3s (IC50 = 0.247 μM) was the most potent one. More importantly, compound 3s inhibited LSD1 in the cellular level and downregulated the expression of programmed cell death-ligand 1 (PD-L1) in BGC-823 and MFC cells to enhance T-cell killing response. An in vivo study confirmed that compound 3s can inhibit MFC cell proliferation without significant toxicity in immunocompetent mice. Taken together, our findings indicated that the novel LSD1 inhibitor 3s tethering a phenothiazine scaffold may serve as a lead compound for further development to activate T-cell immunity in gastric cancer.

[1]  Ning Wang,et al.  LSD1 deletion decreases exosomal PD-L1 and restores T-cell response in gastric cancer , 2022, Molecular cancer.

[2]  Yuting Shi,et al.  Annual review of lysine-specific demethylase 1 (LSD1/KDM1A) inhibitors in 2021. , 2021, European journal of medicinal chemistry.

[3]  Hong-min Liu,et al.  An Update of Lysine Specific Demethylase 1 Inhibitor: A Patent Review (2016-2020). , 2021, Recent patents on anti-cancer drug discovery.

[4]  A. Mardinoğlu,et al.  Lysine demethylase LSD1 delivered via small extracellular vesicles promotes gastric cancer cell stemness , 2021, EMBO reports.

[5]  Hong-min Liu,et al.  Reversible Lysine Specific Demethylase 1 (LSD1) Inhibitors: A Promising Wrench to Impair LSD1. , 2021, Journal of medicinal chemistry.

[6]  Hongmin Liu,et al.  Tranylcypromine based LSD1 inhibitor: Summary and Prospective. , 2020, Journal of medicinal chemistry.

[7]  M. Dawson,et al.  Targeting the epigenetic regulation of antitumour immunity , 2020, Nature reviews. Drug discovery.

[8]  Guochao Liao,et al.  Natural products as LSD1 inhibitors for cancer therapy , 2020, Acta Pharmaceutica Sinica B.

[9]  Hong-min Liu,et al.  LSD1 deletion represses gastric cancer migration by upregulating a novel miR-142-5p target protein CD9. , 2020, Pharmacological research.

[10]  Liying Ma,et al.  Exploration of 5-cyano-6-phenylpyrimidin derivatives containing an 1,2,3-triazole moiety as potent FAD-based LSD1 inhibitors , 2020, Acta pharmaceutica Sinica. B.

[11]  Guochao Liao,et al.  LSD1/KDM1A inhibitors in clinical trials: advances and prospects , 2019, Journal of Hematology & Oncology.

[12]  Zhe-Sheng Chen,et al.  Derivative of 5-cyano-6-phenylpyrimidin antagonizes ABCB1- and ABCG2-mediated multidrug resistance. , 2019, European journal of pharmacology.

[13]  Eko Aditya Rifai,et al.  A Comparative Linear Interaction Energy and MM/PBSA Study on SIRT1–Ligand Binding Free Energy Calculation , 2019, J. Chem. Inf. Model..

[14]  Kuojun Zhang,et al.  Development of Inhibitors of the Programmed Cell Death-1/Programmed Cell Death-Ligand 1 Signaling Pathway. , 2018, Journal of medicinal chemistry.

[15]  M. Huang,et al.  Inhibition of Histone Lysine-specific Demethylase 1 Elicits Breast Tumor Immunity and Enhances Antitumor Efficacy of Immune Checkpoint Blockade , 2018, Oncogene.

[16]  G. Freeman,et al.  LSD1 Ablation Stimulates Anti-tumor Immunity and Enables Checkpoint Blockade , 2018, Cell.

[17]  Jedd D. Wolchok,et al.  Cancer immunotherapy using checkpoint blockade , 2018, Science.

[18]  P. Zhang,et al.  Advances toward LSD1 inhibitors for cancer therapy. , 2017, Future medicinal chemistry.

[19]  Cheng Li,et al.  GEPIA: a web server for cancer and normal gene expression profiling and interactive analyses , 2017, Nucleic Acids Res..

[20]  Jedd D. Wolchok,et al.  PD-L1 (B7-H1) and PD-1 pathway blockade for cancer therapy: Mechanisms, response biomarkers, and combinations , 2016, Science Translational Medicine.

[21]  Frederick M. Lang,et al.  Preclinical activity of combined HDAC and KDM1A inhibition in glioblastoma. , 2015, Neuro-oncology.

[22]  Zhijia Wang,et al.  Design, synthesis, and structure-activity relationship of novel LSD1 inhibitors based on pyrimidine-thiourea hybrids as potent, orally active antitumor agents. , 2015, Journal of medicinal chemistry.

[23]  D. Mobley,et al.  Triazole-dithiocarbamate based selective lysine specific demethylase 1 (LSD1) inactivators inhibit gastric cancer cell growth, invasion, and migration. , 2013, Journal of medicinal chemistry.

[24]  Daniel R Roe,et al.  PTRAJ and CPPTRAJ: Software for Processing and Analysis of Molecular Dynamics Trajectory Data. , 2013, Journal of chemical theory and computation.

[25]  T. Somervaille,et al.  LSD1 inhibition: a therapeutic strategy in cancer? , 2012, Expert opinion on therapeutic targets.

[26]  B. Ponder,et al.  Overexpression of LSD1 contributes to human carcinogenesis through chromatin regulation in various cancers , 2011, International journal of cancer.

[27]  R. Schüle,et al.  Lysine-specific demethylase 1 (LSD1) is highly expressed in ER-negative breast cancers and a biomarker predicting aggressive biology. , 2010, Carcinogenesis.

[28]  D. Tieleman,et al.  The MARTINI force field: coarse grained model for biomolecular simulations. , 2007, The journal of physical chemistry. B.

[29]  Yang Shi,et al.  Histone Demethylation Mediated by the Nuclear Amine Oxidase Homolog LSD1 , 2004, Cell.

[30]  T. Darden,et al.  Particle mesh Ewald: An N⋅log(N) method for Ewald sums in large systems , 1993 .

[31]  A. Becke.  Density-functional thermochemistry. III. The role of exact exchange , 1993 .

[32]  B. Brooks,et al.  Langevin dynamics of peptides: The frictional dependence of isomerization rates of N‐acetylalanyl‐N′‐methylamide , 1992, Biopolymers.

[33]  Hermann Stoll,et al.  Results obtained with the correlation energy density functionals of becke and Lee, Yang and Parr , 1989 .

[34]  H. Berendsen,et al.  Molecular dynamics with coupling to an external bath , 1984 .

[35]  G. Ciccotti,et al.  Numerical Integration of the Cartesian Equations of Motion of a System with Constraints: Molecular Dynamics of n-Alkanes , 1977 .

[36]  S. Snyder,et al.  Phenothiazine drugs: structure-activity relationships explained by a conformation that mimics dopamine. , 1975, Proceedings of the National Academy of Sciences of the United States of America.

[37]  S. Snyder,et al.  Chlorpromazine and dopamine: conformational similarities that correlate with the antischizophrenic activity of phenothiazine drugs. , 1971, Proceedings of the National Academy of Sciences of the United States of America.